Earnings call
Aurobindo Pharma Q2 FY26 earnings call
By DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person.
Transcript filed .
The company filed one other transcript for this quarter. This page reads the one with the speakers marked, then the most statements.
Growth over the next 2 years will be driven by ramp-up of its Pen-G facility, commercialization of its biosimilar portfolio and rapid progress in its biologic CMO. The company started operations of Pen-G on July 1, 2025, after receiving the necessary regulatory approval. Consolidated revenues grew 6% year-on-year to ₹8,286 crores in the second quarter ended September 30, 2025, driven by strong U.S. formulation base business and continued momentum in European and growth market operations. U.S. base business saw continued demand supported by increased volumes and new product launches in the second quarter ended September 30, 2025. The company has about 10.2% prescription coverage in the US, the largest.
The numbers management gave
Results
- Consolidated revenues grew 6% year-on-year to ₹8,286 crores in the second quarter ended September 30, 2025, driven by strong U.S. formulation base business and continued momentum in European and growth market operations.
Show source
• Our consolidated revenues grew by 6% year-on-year to ₹8,286 crores, reflecting sustained business momentum through the first half of FY26.
- EBITDA was ₹1,678 crores, with a margin of 20.3%, and grew 7% year-on-year in the second quarter ended September 30, 2025.
Show source
• EBITDA for the quarter stood at ₹1,678 crores with a margin of 20.3%, demonstrating a 7% year -on-year growth.
- Formulation business grew 10% year-on-year to ₹7,325 crores, contributing approximately 88% of total consolidated revenues in the second quarter ended September 30, 2025, led by performance in the U.S., Europe and key growth markets.
Show source
The overall Formulation business reported a year-on-year growth of 10%, with revenues reaching ₹7,325 crores, contributing approximately 88% of the total consolidated revenues.
- API business contributed 12% of overall revenues, amounting to ₹961 crores, in the second quarter ended September 30, 2025, reflecting market dynamics in the current pricing environment.
Show source
The API business contributed to 12% of the overall revenues, amounting to ₹961 crores, reflecting the ongoing market dynamics in the current pricing environment.
- U.S. revenues were $417 million in the second quarter ended September 30, 2025.
Show source
U.S. Formulation: U.S. revenues stood at $417 million.
- Excluding gRevlimid, Aurobindo Pharma Limited's U.S. Oral Solid business grew 6% quarter-on-quarter in the second quarter ended September 30, 2025.
Show source
Excluding gRevlimid, the U.S. Oral Solid delivered a healthy 6% quarter-on-quarter growth, underscoring the strength and resilience of our diversified portfolio.
Show 16 more statements
Results
- The company launched 6 new products, filed 13 ANDAs and received 7 final approvals in the second quarter ended September 30, 2025.
Show source
During the quarter, we launched 6 new products, 13 ANDAs and received 7 final approvals demonstrating robust pipeline execution and continued regulatory progress.
- European business grew 18% year-on-year to ₹2,480 crores, or €243 million, in the second quarter ended September 30, 2025; the company is on track to support a 1 billion annual revenue milestone from Europe by the end of FY26.
Show source
European business: The European business maintained a strong growth trajectory, delivering 18% year -on-year revenue growth amounting to ₹2,480 crores, in Euro terms amounting to €243 million this quarter.
- Growth markets revenue increased 9% year-on-year to ₹882 crores or 101 million in the second quarter ended September 30, 2025, driven by strong volume growth and a resilient commercial footprint.
Show source
Growth Markets: Revenue from the growth markets increased by 9% year -on-year to ₹882 crores or 101 million driven by strong volume growth and resilient commercial footprint.
- ARV revenue grew 69% year-on-year to ₹325 crores or 37 million in the second quarter ended September 30, 2025.
Show source
ARV Formulation: ARV revenue grew by 69% year-on-year, reaching ₹325 crores or 37 million.
- Gross margin was 59.7% in the second quarter ended September 30, 2025, compared with 58.8% last quarter, supported by raw material prices and business mix.
Show source
Operational and Financial Highlights: Gross margins for the quarter stood at 59.7% compared to 58.8% last quarter, supported by raw material prices and the business mix.
- Gross contributions stood at ₹4,947 in the second quarter ended September 30, 2025.
Show source
Gross contributions stood at ₹4,947.
- Excluding gRevlimid, Aurobindo Pharma Limited's sales increased approximately 7%, gross profit increased 10%, and EBITDA increased 14% quarter-on-quarter in the second quarter ended September 30, 2025.
Show source
Excluding gRevlimid, on a quarter-on-quarter our Sales have increased approximately by 7%, Gross Profit by 10%, and EBITDA by 14% respectively.
- R&D expenditure was ₹414 crores, or 5% of total revenue, in the second quarter ended September 30, 2025.
Show source
R&D expenditure was ₹414 crores, representing 5% of the total revenue, thereby reaffirming our continued focus on innovation and advancing a robust pipeline of complex generics and specialty therapeutics.
- The company produced around 1,050 MT of Pen-G during the second quarter ended September 30, 2025, operating at 40%-50% capacity, equivalent to approximately 6,000 MT production on an annualized basis.
Show source
During the quarter, we produced around 1,050 MT by operating at 40%-50% capacity, amounting to approximately 6,000 MT production on an annualized basis.
- Average finance costs declined to 4.7% compared with previous quarters in the second quarter ended September 30, 2025.
Show source
Average finance costs declined to 4.7% compared to previous quarters, reflecting effective treasury and cashflow management.
- PAT was ₹848 crores in the second quarter ended September 30, 2025.
Show source
PA T for the quarter was ₹848 crores.
- China operations incurred a loss of around a million dollar in the second quarter ended September 30, 2025; the company expects to achieve breakeven between Q3 and Q4, after which China will contribute to EBITDA growth.
Show source
Trying to understand that… S. Subramanian: No, China, as on date in the quarter I will be incurring a loss of around maybe a million dollar but probably we will be able to achieve the breakeven between Q3 and Q4 and after that China will start moving up in the overall contributing to the growth of the EBITDA growth.
- The company said losses at some businesses, including Pen-G (Lyfius), are incurred at PBT level and it does not take tax credit on those losses until the businesses start making a profit; this makes the tax rate appear to be 35% although it is actually 25%, while tax returns carry the losses and tax credit.
Show source
So, because of that it appears like we are having a 35% tax rate but in reality , it's only 25% whereas the tax returns will carry the losses, tax credit.
- Injectables are about 10% of Aurobindo Pharma's European business, which is touching [EUR] 100- million; Aurobindo expects a quantum jump in FY27 as products from Eugia III begin to contribute, and margins are at 20 levels, high teens.
Show source
And, of course, the margin percentage wise, yes, we are touching at 20 levels, high teens.
Money and capital
- Net CapEx was $106 million in the second quarter ended September 30, 2025.
Show source
The Net CapEx for the quarter stood at $106 million, in line with our strategic priorities of enhancing our manufacturing capabilities, strengthening compliance, and accelerating automation.
- The company generated net cash inflows before dividend of $57 million during the second quarter ended September 30, 2025; its net cash position, including investment, was $170 million as of September 30, compared with $140 million as of 30th June’2025.
Show source
We generated net cash inflows before dividend $57 million during the quarter resulting in an improved net cash position, including investment of $170 million as of September 30 th, compared to $140 million as of 30 th June’2025.
What it expects ahead
What management expects
- Growth over the next 2 years will be driven by ramp-up of its Pen-G facility, commercialization of its biosimilar portfolio and rapid progress in its biologic CMO.
Show source
Summary: To summarize, our next 2 years, our growth will be driven by several key factors including ramp-up of our Pen-G facility, commercialization of the biosimilar portfolio and rapid progress in our biologic CMO.
- The company expects gross margin to increase slightly once the Pen-G plant is fully operational and says it may cross 60%.
Show source
Once it's operated fully, probably we may cross 60% also.
- The company plans to submit marketing authorization applications for Denosumab biosimilars for Prolia and Xgeva to the European Medicines Agency in April ’2026; it expects the FDA submission in the July quarter of 2026 Calendar Year.
Show source
So , April is when the European submission for this biosimilar will happen , and the FDA submission we think that we can be able to do it in the July quarter of 2026 Calendar Year.
- The company believes a Phase 3 study will be relevant for this product with USFDA because it does not have a good PD marker, and its USFDA filing plans have not changed; filing is planned towards the end of the next year.
Show source
That will be towards the end of the next year.
- The company expects about 7 approvals in Europe and possibly a couple of approvals in the US in ’27-’28 for its biosimilar business.
Show source
The ‘27-’28, which I always told, will be the inflection point in the biosimilar business where I expect about 7 approvals in Europe and possibly a couple of approvals in the US on the upside.
- If Aurobindo Pharma files between April -June, it expects the USFDA inspection to happen by the end of Calendar Year 2026.
Show source
So, if we file it somewhere between April -June, then I expect the inspection to happen by the end of the Calendar Year 2026 with the USFDA.
Show 8 more statements
What management expects
- The company is confident of achieving its internal target margin of 20%-21% range in FY26.
Show source
4 Aurobindo Pharma Limited 06 November 2025 Last but not least, we are confident of achieving our internal margin target of 20 %-21% for FY26, as communicated earlier.
- The company expects to sustain the growth in ARV revenue over the medium to long term, following higher volumes and new tender wins across multiple geographies.
Show source
This was primarily fuel by higher volumes and new tender wins across multiple geographies and we expect to sustain this momentum over the medium to long term.
- China OSD site is on track to deliver EBITDA breakeven by Q3-Q4 FY26.
Show source
The site is on track to deliver EBITDA breakeven by Q3 -Q4 FY26, reinforcing its strategic importance to the global network.
- The company expects continued improvement in its Injectable business from continued supply ramp-up, increasing supplies from its China plant to Europe, additional contribution from new launches and the Lannett acquisition in the US.
Show source
We expect continued improvement in Injectable business driven by continued supply ramp - up, increasing supplies from China plant to Europe, additional contribution from a robust pipeline of new launches and the Lannett acquisition in the US, which will further strengthen our market position, expand our portfolio and drive medium -term growth.
- The company will be able to give clear guidance on its margin trajectory once it knows the status of the Pen-G MIP, which it hopes will be known in a month to two months; it expects to provide guidance in February.
Show source
S. Subramanian: I think we will be able to give a clear guidance once we come to know about the status of the Pen-G MIP, right, which hopefully it will happen very soon, maybe a month to two months’ time.
- The company believes it will be able to submit Tocilizumab to the European Medicines Agency in the July quarter next year.
Show source
We believe we will be able to submit this product also in the July quarter next year with the European Medicines Agency.
- The company has pushed Trastuzumab filing with USFDA to the latter half of next year because of supply commitments and the product's lyophilized form, after recalculating capacity and utilization; Denosumab will now be the first filing, followed by Omalizumab.
Show source
So, the first filing would now be Denosumab followed by Omalizumab.
- The company expects volume expansion and a reasonably stable pricing environment to underpin its growth momentum. Replaced by a later filing.
Show source
Our optimism is underpinned by expected volume expansion and reasonably stable pricing environment.
What it is building and selling
Projects and capacity
- The company started operations of Pen-G on July 1, 2025, after receiving the necessary regulatory approval.
Show source
3 Aurobindo Pharma Limited 06 November 2025 Update on Pen-G: During the quarter, we started the operations of Pen-G on July 1, 2025, after getting the necessary regulatory approval.
- OSD facility in China is ramping up toward capacity of 2 billion, backed by European approval of 10 products and 3 local product approvals.
Show source
The OSD facility in China continues to ramp up advancing towards the capacity of 2 billion backed by European approval of 10 products and 3 local product approvals.
- The company committed about ₹1,000 crore of capital investment to establish a 2X15 kL mammalian bioreactor commercial scale facility at TheraNym.
Show source
As I told you, the company committed a capital investment of about ₹1,000 crore to establish 2X15 kL mammalian bioreactor commercial scale facility.
- Dayton site has transitioned into the commercial phase, with manufacturing underway, packaging approval secured and product launches scheduled from January; the site is positioned to start contributing significant revenues in FY27.
Show source
In the US, Dayton has transitioned into the commercial phase with manufacturing underway, packaging approval secured and product launches scheduled from January, positioning the site to start contributing significant revenues in FY27.
- Raleigh site is awaiting regulatory clearance.
Show source
Meanwhile, Raleigh is awaiting regulatory clearance.
- TheraNym expects its project to be ready for inauguration sometime in June, July next year.
Show source
TheraNym continues to make a steady progress on executing this project and I believe this project will be ready for inauguration sometime in June, July next year.
Show 10 more statements
Demand and pricing
- U.S. base business saw continued demand supported by increased volumes and new product launches in the second quarter ended September 30, 2025.
Show source
This quarter also saw continued demand from our base business supported by increased volumes and new product launches.
- The company says Injectable pricing erosion remains single digit overall, although erosion can be higher or lower for individual one-off products.
Show source
It is only thing, as Swami rightly said, they can be a one-off product here and there where the erosion can be higher or lower but on an overall level it is still single digit.
Segments
- The company has about 10.2% prescription coverage in the US, the largest.
Show source
As far as US is concerned, we have a prescription of about 10.2%, which is the largest.
- The company has upward of 80% portfolio coverage in the representative market, excluding biosimilars and inhalation products, and is striving to reach 85% to 90% coverage.
Show source
Coming to the portfolio, on the representative market, if you can assess, we are on upward of 80% of portfolio coverage and we are constantly striving to touch that 85% to 90% levels.
- The company reported a successful Phase 1 study outcome for denosumab and completion of its Phase 3 study. Aurobindo Pharma announced a successful Phase 3 clinical study outcome for its Denosumab biosimilar, following a trial conducted entirely in Europe in 446 patients across 5 European countries and 40 clinical sites.
Show source
We conducted a Phase 3 trial entirely in Europe in 446 patients enrolled across 5 European countries and I think 40 clinical sites.
- The company successfully completed patient recruitment in its Phase 3 trial of Omalizumab, a biosimilar to Xolair.
Show source
Likewise, Omalizumab, which is a very important product, a biosimilar to Xolair, we have successfully completed patient recruitment in our Phase 3 trial.
- The company completed a clinical PK/PD study for Tocilizumab and received a Phase 3 clinical study waiver from the European Medicines Agency, enabling it to fast track the product.
Show source
So, we went to European Medicines Agency , my regulatory team was able to get a Phase 3 clinical study waiver with the European Medicines Agency which means that now we are doing everything to fast track Tocilizumab which is also immunology product.
Deals and partners
- The company strengthened its collaboration with MSD by signing a second product contract during the last quarter, adding two additional 15 kL mammalian bioreactor lines as part of Block 2 in the same facility.
Show source
During the last quarter we further strengthened the collaboration with MSD by signing a second product contract with them , to support this expanded scope t wo additional 15 kL mammalian bioreactor lines are being added as part of Block 2 in the same facility.
- The company successfully invoiced and delivered its first batch of biosimilar in the European market.
Show source
To your second question , Shyam, on the EU launch and supplies , we are pleased to share that we have successfully invoiced and delivered our first batch of biosimilar in the European market, which is an important milestone.
- The company is negotiating a couple of strategic deals in the European market to broaden its product portfolio and maximize its supply potential, and expects to share more details in the next quarter.
Show source
13 Aurobindo Pharma Limited 06 November 2025 Also, what is important to note is, we are in the process of negotiating a couple of strategic deals in European market that will broaden our product portfolio and maximize our supply potential.
Risks, rules and outside factors
Rules and policy
- The company has made a representation to the government to implement the minimum import price, which it says will support Pen-G ramp-up toward 100% capacity utilization and 15,000 MT production in a very short term.
Show source
Like other companies, we have made our representation to the government to implement the minimum import price, which will support the further ramp -up in achieving 100% capacity utilization, taking the production to 15,000 MT in a very short term.
- Companies investing anywhere between [USD] 50-150 million in clinical studies may not need to expend that much when a high quality biosimilar characterized well vis-à-vis the originator biologic receives a Phase 3 waiver on a case-to-case basis.
Show source
• Two, because if you develop a high quality biosimilar that is characterized well vis-à- vis originator biologic, the chances are , on a case-to-case basis you will get a Phase 3 waiver, which means that the companies which were investing anywhere between [USD] 50-150 million in conducting these clinical studies don't need to expend that much now.
- The company expects immunogenicity requirements to increase, while timelines will shrink and investments will no longer be required to the extent made before. Replaced by a later filing.
Show source
But having said that, the timelines will shrink, the investments will no longer be required to the extent that we were making before.
Everything else said on the call
Group structure
- The company may make small acquisitions in India but will not do a big one; its India turnover is around ₹275-₹300 crore per year and may increase by another ₹100 crore.
Show source
As of now, we are doing around a turnover of something like ₹275-₹300 crore per year and probably we may take it by another ₹100 crore; like that only we will do.
- Assuming a $4 billion price for Zentiva and 100% leverage, Aurobindo Pharma's interest coverage would be more than 2 times, 2.5 times; the company said the decision depends on the case and described Zentiva as a very unique case.
Show source
S. Subramanian: No, see, Zentiva also, if you really see, assuming $4 billion, we have not given any number, assuming $4 billion the interest coverage will be more than 2 times, 2.5 times, right, even assuming 100% leverage.
What the company said on its earnings call, taken from its own transcript. Not advice.
Questions and answers
Question
Damayanti Kerai: Good morning, everyone. Thank you for the opportunity. Sir, my first question is on Generic Injectable business in the US. Sorry, I missed your comment, you mentioned it grew 6% quarter-on-quarter. So, a few clarifications. Are we broadly back to the level where disruption happened? And how do you see this business shaping up in the next two years? And if you can just talk a bit about some of the key pipeline products which you may have in your pipeline.
Answer, yugandhar puvvala
Yugandhar Puvvala: Hi Damyanti. So, still we are not back to the pre -disruption levels. I think we still have another 5 -10 million dollars to go to reach that level. But it is mainly driven not because of existing products growth but because we don't have the new products to offset the single -digit price decline . So, we still have a quarter or two to go to come back to the pre-disruption levels. But the production is back on track and there is no issue there. Going forward into the future what we are looking at is – 1.
Answer, yugandhar puvvala
Number one, on the Injectable side we have some interesting products and, hopefully, like once Eugia III gets the reinspection and approvals, we have multiple products to launch. Second is with respect to our Vizag and Vizag commercialization and some new products coming from Vizag plant. And third from a speciality portfolio, we have a lot of Oncology oral solids which we are expected to launch in Q4 and Q1 of next year. So, there are multiple levers going forward. 5 Aurobindo Pharma Limited 06 November 2025 Damayanti Kerai: Sure.
Question
And if you can just remind us about when you are expecting Eugia III reinspection?
Answer, yugandhar puvvala
Yugandhar Puvvala: Yeah. Eugia III, like we have already requested FDA in the end of Q2. And now we have the confirmation from FDA granting a reinspection for Eugia III. So, we received the official letter from FDA on 25 th of September saying that they have accepted our request for reinspection. So, as per GDUFA III guidelines, normally it is any time from now till for 8 months, okay. So, they can come in any time for the reinspection.
Question
Damayanti Kerai: Okay. So, majority of new launches which we are expecting is broadly tied up to Eugia III clearance, right, if my understanding is correct?
Answer, yugandhar puvvala
Subbu sir, you mentioned now the capacity has reached up to 6000 MT on an annualized basis, right. So, when you go and discuss with government for the PLI benefit, what kind of scale up by then you are expecting and what is the amount?
Answer, s subramanian
S. Subramanian: No, we are not running all the fermenters, we are running only 40%-50% of the fermenters. We have represented to the government and as and when any policy changes take place, we will ramp it up in a very short time.
Question
Damayanti Kerai: Okay. Okay, I'll get back in the queue. Thank you.
Answer, s subramanian
S. Subramanian: That's a good question, Neha. As I explained to you, we have been improving on the yield, etc. We are nearing the breakeven from the current operations, etc. We have been doing around 6,000 tons per annum. See, we are doing 500 tons per month. I can increase it to 800 immediately, not a big issue , right. Once I touch 800, certainly it will 6 Aurobindo Pharma Limited 06 November 2025 contribute to the EBITDA. But having said that, we also need to look at it at what price we need to take that and move on. So, that is what we are looking for the policy changes.
Answer, s subramanian
As and when it happens, we will do that. As a Plan B, what you are saying is, we have been continuously working on improving the yields and other things. That is going in a very positive direction, as informed to you in earlier this one . So, we are ready with Plan B in case there are any issues but I don't think that is necessary in my view.
Question
Neha Manpuria: Yeah. So, my question is, have we seen any change in the price erosion trend in the US in the recent months? And with this disruption in one of our competitor’s plant, how does that position us to probably gain more volume in the market? Do you see that as an opportunity in the near term?
Answer, swami iyer
Swami Iyer: So, when we take it as a basket, we think we are close to neutral. We have a little bit of erosion with very low single digit , I would say it's closer to 1 for the quarter. And this is based on an overall basket of products. There are some increases, there are some decreases. However, I have to make one point here. We did have some products which were opportunistic, which for a limited period you get some better opportunity in terms of pricing and volume. Those things, when they taper down, when a competitor comes in those prices will go down when you are a single player or when you have just one competitor, later when somebody enters, it could go down.
Answer, swami iyer
So, we have seen such phenomena for a few products. 7 Aurobindo Pharma Limited 06 November 2025 In any quarter, if you take, you will always have one product which you have either got a shortage and because of that there are opportunities and there are products which go out. So, net-net, I think we are still at a comfortable stage.
Question
Neha Manpuria: Understood. And, Yugandhar, any colour from you on the Injectable pricing? I think you said single digit erosion, has that increased in the recent months?
Answer, yugandhar puvvala
Yugandhar Puvvala: No, it is a similar trend. It is only thing, as Swami rightly said, they can be a one-off product here and there where the erosion can be higher or lower but on an overall level it is still single digit.
Question
Tushar Manudhane: Good Morning, Sir. Sir, on the EBITDA margin first, like your guidance of 20%-21% for FY26, now that Pen-G plant is largely stable, closer to EBITDA breakeven, Eugia related operational cost is largely done, probably inspection can only move up in terms of profitability from here on. So, if I have to extend this for FY27 maybe without considering the inspection outcome of Eugia III, how do we see the margin trajectory from here on?
Answer, s subramanian
S. Subramanian: I think we will be able to give a clear guidance once we come to know about the status of the Pen-G MIP, right, which hopefully it will happen very soon, maybe a month to two months’ time. So, we will be able to tell you very clearly in the month of February. Tushar Manudhane: Got it. Sir, China plant operational cost, how much that is? Trying to understand that… S. Subramanian: No, China, as on date in the quarter I will be incurring a loss of around maybe a million dollar but probably we will be able to achieve the breakeven between Q3 and Q4 and after that China will start moving up in the overall contributing to the growth of the EBITDA growth.
Question
Tushar Manudhane: Got it. In fact, trying to understand that even without let's say MIP related benefit on Pen-G, still how much is the scope to improve the EBITDA margin from the current 20%-21% for FY26 or FY27?
Answer, s subramanian
S. Subramanian: Tushar, you are putting a lot of variables like don't consider Eugia III, don't consider Pen-G then it will remain the same because these are all the key drivers which is expected to take it up in the next year.
Question
Tushar Manudhane: Understood. Sir, secondly on Europe, which has been sort of a robust growth for now almost 3 years and reaching a billion dollars, so given this size of the business do we think that we will be able to still sustain mid-teens sort of a growth over next 2-3 years? 8 Aurobindo Pharma Limited 06 November 2025 V. Murlidharan: Sure.
Answer, v murlidharan
Yeah, Tushar, thank you for raising this question. Just one interesting correction, we are now touching billion euros mark, whereas last financial year we were at a touching distance of billion dollars but now we are well on track for billion euros. And, yes, as you have seen in the last 3 years, QOQ we are demonstrating growth and considering my all major countries contributors - France, Portugal, Netherlands and Germany continue to demonstrate this growth trajectory. I am very confident in the coming quarters and period as well there will be sustained growth.
Question
Bino: Hi. Good morning and good evening. Subbu Sir, if I heard correctly, you said the EBITDA excluding Revlimid has improved 14% QOQ, is that correct?
Answer, s subramanian
S. Subramanian: That is also one and Sales has grown up by about 7%, Gross Profit also grown up by 10%. I think overall there is improvement across the businesses which is what driving the overall improvement of the EBITDA. Bino: Okay. And the gross margin QOQ has gone up despite lower Revlimid, what has driven that? What has changed so much in the product mix?
Answer, s subramanian
S. Subramanian: See, one is, if you really see the formulation products have gone up this quarter compared to API, right. That is one small product change. And, second, if you really see Europe has been continuously growing , so the operating leverage is getting increased quarter-on-quarter which is also helping us. And the third point is, there is a product mix which is happening across US also. I may not like to get into the details in terms of which segment, which product, etc. but there is a good amount of product mix changing place in US which is also helping. So, it's a combination of multiple factors which is helping to grow the thing. And the last one is once the Pen-G comes, the gross margin will be very high because the major cost apart from the raw material is the coal.
Answer, s subramanian
So, you will be able to see a slight increase in the gross margin once the Pen-G plant comes full operational. Once it's operated fully, probably we may cross 60% also. Bino: Understood. And Revlimid, was it minimal for the quarter and are we completely done with it? S. Subramanian : It's a minimal for the quarter. Bino: Okay. And next quarter will be close to zero?
Answer, s subramanian
S. Subramanian: See, basically, some of the businesses are incurring losses, which you know, at a PBT level like Pen-G(Lyfius), some of the other businesses. We don't take tax credit on the losses. We will take only as and when it started making profit, we'll adjust it. So, because of that it appears like we are having a 35% tax rate but in reality , it's only 25% whereas the tax returns will carry the losses, tax credit. In books of account , we don't. Bino: Okay. So, once they become profitable, the reported tax rate can fall below 25%?
Show 13 more questions
Question
Tarang Agarwal: Hi, good morning. Couple of questions, Sir. Both on US and Europe, if you could give us a sense on what's the portfolio coverage currently? Specifically in US, how does Lannett help it improve say quantitatively and what are the steps to improve? And similarly in Europe, things get a little complicated in Europe because it's a confederation of many countries. So, if you could give a more granular insight on some of your major markets. That's on portfolio coverage. On cashflows, CapEx intensity of the business continues to be reasonably high despite reasonable amount of capacities which continue to be unutilized. H1, it's already at ₹1500 crores, so how should we really now Pe
Answer, swami iyer
Swami Iyer: Let me talk about US first, Subbu. After that, probably Murali can talk about Europe or you can generally talk about other countries. As far as US is concerned, we have a prescription of about 10.2%, which is the largest. So, that tells you the coverage. It's very fairly large across all segments and we have been growing. We have been growing. Now, this quarter we have seen some momentum in terms of seasonality , so that has also helped us.
Answer, swami iyer
That's as far as the US is concerned . And when you talk about Lannett specifically, Lannett has a number of products which are good additions to our portfolio like the ADHD products and we are very excited to have those products in our portfolio once the merger is done. We are still awaiting the FTC approval, as you may be aware , and that's a process we have to go through.
Question
Tarang Agarwal: Sir, if I could just chip in. I mean, I understand that you've got north of 10% volume share but does it come after covering say 50% of the market or does it come after covering 60% of the market? It's really that's the metric that I was looking for. 10 Aurobindo Pharma Limited 06 November 2025 Swami Iyer: So, I didn't get your question.
Answer, swami iyer
I don't know what is that 50% and 60% you are talking about. You are talking about products?
Answer, swami iyer
Swami Iyer: Oh! Portfolio coverage. Okay. So, we are into all segments, all therapeutic areas. I would say that we are probably around 50% or more but, you know, it does not cover all the presentations of a product. For example, now foam, let us take foam as one, some of the derma areas we have still not covered. So, I would only say that we have significant coverage in the therapeutic area.
Answer, swami iyer
So, I don't have the exact percentage but that's where we are.
Question
Tarang Agarwal: Sure.
Answer, v murlidharan
V. Murlidharan: Tarang, maybe I can touch upon the European part of the query. Murali here. So, you touched upon the portfolio breadth and also the complexities in Europe under which we are operating in. So, let me touch the second point. Yes, we are talking of multiple regulators, multiple language packs, different language packs and fragmented market and different market archetypes, whether it is a tender generic market or pharmacy driven or prescription driven. Across all these, we have demonstrated our success. There is a very well-set system - frontend, commercial infrastructure, well-motivated team acting across these different markets and that way we are able to overcome the challenges.
Answer, v murlidharan
In addition to the regulators, we are also answerable to the European Commission, European Medicine Agency. Newer challenges like on nitrosamine we keep hearing but we are able to overcome all these with all our efforts. Coming to the portfolio, on the representative market, if you can assess, we are on upward of 80% of portfolio coverage and we are constantly striving to touch that 85% to 90% levels. Of course, here I have excluded biosimilars and inhalation products but there again very soon we will be making our launches.
Question
Tarang Agarwal: Sir, when you say represented markets, what do you mean? Because I felt there was an asterisk to it when you called the term represented market.
Answer, v murlidharan
V. Murlidharan: That’s where I qualify telling some of the biosimilars range and inhalation range which I have excluded but, otherwise, the generic-generic market in which we are operating in we are able to have over 80% of the portfolio addressed.
Question
Tarang Agarwal: Okay. Yeah, any comment on biosims imilars because you specifically spoke about CapEx there, Sir? Dr. Satakarni Makkapati: Tarang, hi.
Answer, satakarni makkapati
Biosimilars, as you know that we have invested in capacity expansion 1.5 years ago. So, this is not a new CapEx per se. I told you in the Earnings Call some time back that we have we are adding to two 2,500 litres mammalian bioreactors to the existing CuraTeQ facility. Now, after 18 months of the CapEx approval or maybe 2 years of CapEx approval, those lines are now getting commissioned. Likewise , to make us commercial ready and to ensure a good supply chain , we also needed to add filling capacities. So, as part of the last year's, (2024), CapEx approval, we are adding a vial filling line to the filling capacities at CuraTeQ. So, those equipments will come on line.
Answer, satakarni makkapati
I think the bioreactors will come on line, will be fully commissioned and qualified this quarter. The filling line will be fully on line and qualified by June or the July quarter next fiscal. With respect to TheraNym, as you know, that is another CapEx investment for Aurobindo. As I told you, the company committed a capital investment of about ₹1,000 crore to establish 2X15 kL mammalian bioreactor commercial scale facility. TheraNym continues to make a steady progress on executing this project and I believe this project will be ready for inauguration sometime in June, July next year. So, that's the CapEx exposure that we continue to have. During the last quarter we further strengthened the collaboration with MSD by signing a second product contract with them , to support this expanded scope t wo additional 15 kL mammalian bioreactor lines are being added as part of Block 2 in the same facility.
Answer, satakarni makkapati
So, that's another CapEx exposure that you will be witnessing. Otherwise, what our CapEx commitments, that Subbu has been talking about, the fiscal prudence in terms of expenditure is extremely tight at Aurobindo. So, we are very conscious of the fact on the question that you have raised and we are maintaining prudence in expending this CapEx. Tarang Agarwal: Wonderful, Sir! And I don't know if this was called out before but congrats on the expansion of scope with MSD. Thank you. Dr. Satakarni Makkapati: Thank you.
Question
Shyam Srinivasan: Yeah, hi. Good morning. Thank you for taking my question. Dr. Satakarni, just sticking to biosimilar commercialization and even the pipeline updates, if you could share, please. Thank you. 12 Aurobindo Pharma Limited 06 November 2025 Dr. Satakarni Makkapati: So, it's pretty interesting in terms of the last quarter that we had.
Answer, satakarni makkapati
We announced a successful Phase 3 clinical study outcome for our Denosumab biosimilar. We conducted a Phase 3 trial entirely in Europe in 446 patients enrolled across 5 European countries and I think 40 clinical sites. We are working towards submitting the marketing authorization applications for Denosumab biosimilars both for Prolia and Xgeva biosimilars to European Medicines Agency in April ’2026. Now, I have given this guidance before that I would like to submit the MA application in January but considering my other clinical commitments on the facility availability , the validation batches are taking time. So , April is when the European submission for this biosimilar will happen , and the FDA submission we think that we can be able to do it in the July quarter of 2026 Calendar Year. So, this is a good development for us. Likewise, Omalizumab, which is a very important product, a biosimilar to Xolair, we have successfully completed patient recruitment in our Phase 3 trial.
Answer, satakarni makkapati
This is in chronic spontaneous urticaria . I believe that we will be ready to submit the European Marketing Authorization application in June, July ‘2026 and a quarter later in the US. So, we are on track with this product. An important development is for Tocilizumab, which hitherto was not part of our regulated market plans. We have completed a clinical PK/PD study for Tocilizumab already. So, we went to European Medicines Agency , my regulatory team was able to get a Phase 3 clinical study waiver with the European Medicines Agency which means that now we are doing everything to fast track Tocilizumab which is also immunology product. We believe we will be able to submit this product also in the July quarter next year with the European Medicines Agency.
Answer, satakarni makkapati
We will start engaging with the USFDA to discuss about the possibility of a Phase 3 clinical study waiver for Tocilizumab. So, Tocilizumab, I haven't talked about this product before but now this comes into the filing domain in the next year from us. Bevacizumab ; there is an interesting update . You know that we have completed a Phase 1 study and we have got an approval for our Bevqolva biosimilar in UK. Last, I am told, it's already available in hospitals in UK for purchase from yesterday. With European Medicines Agency we had a scientific advice and we received a waiver for Phase 3 clinical study , which means that I need not wait until the study completion , which is late next year , to submit the file with Europe. We will be able to also submit this file.
Answer, satakarni makkapati
We are planning to submit this file in April’2026 with Europe. With USFDA, we still believe for this product because it doesn't have a good PD marker, we still believe the Phase 3 study will be relevant. So, the USFDA filing plans don't change. That will be towards the end of the next year. So, you can see the portfolio is progressing really well. To your second question , Shyam, on the EU launch and supplies , we are pleased to share that we have successfully invoiced and delivered our first batch of biosimilar in the European market, which is an important milestone. Currently , we are focusing on streamlining our testing activities with the CRO partners to ensure timely testing and compliant QP release of products.
Answer, satakarni makkapati
At the same time , we are also actively aligning our manufacturing and supply capacities so that from March ’2026 we will be able to supply continuously to our European partners. 13 Aurobindo Pharma Limited 06 November 2025 Also, what is important to note is, we are in the process of negotiating a couple of strategic deals in European market that will broaden our product portfolio and maximize our supply potential. We expect to share more clarity and details on these developments in the next quarter. Overall, I remain confident in our European supply roadmap and also the emerging market roadmap that we are putting together and we are committed to delivering value to patients and partners from 2026 onwards. The ‘27-’28, which I always told, will be the inflection point in the biosimilar business where I expect about 7 approvals in Europe and possibly a couple of approvals in the US on the upside. Hope this answers your question.
Question
Shyam Srinivasan: Yeah. Thank you, Sir. Just one sub question is on the new biosimilar guidelines in the FDA and from a competitive intensity standpoint do you now see a lot more of your peers who have probably skirted this opportunity, I'm talking Indian peers, to start looking at it seriously and are you worried about it at all? Dr. Satakarni Makkapati: It's a very interesting question.
Answer, satakarni makkapati
I can give my perspective. In October’2025, the FDA released a new draft guidance aimed at streamlining and simplifying the biosimilar approval process. Now, the way I read the guidance, the draft guidance, is the key regulatory shift, the language is important, please read the language that I am talking about, the key regulatory shifts include reducing the reliance on comparative efficacy studies. So, it is not about eliminating comparative efficacy studies at this point but, eventually, just like Health Canada, European Medicines Agency and MHRA, I believe USFDA will also reach a point where the need for Phase 3 efficacy studies will be removed. But right now, it is about reducing the reliance on comparative efficacy studies and eliminating the requirement of interchangeability. And if you are following my Earnings Calls for the last 2 -3 years, I have been telling that interchangeability designation will go.
Question
Kunal Dhamesha: Hi. Thank you for the opportunity. Since we are quite confident of getting minimum import price for Pen-G, if you could highlight that would it be only for the Pen-G HS code? And, secondly, what is the range that we are looking at? What is the representation that we have made in terms of what should be the minimum import price? That would be helpful.
Answer, s subramanian
S. Subramanian: Kunal, all the questions are very relevant because it is already in the review by the DOP and the government , we will not able to comment on any of your questions. Ultimately, the range, etc., it is their prerogative. What is that they are going to give , etc., is their prerogative. We are making representation , we have been taking up with them etc., but, ultimately, as and when they inform us only, we will be able to communicate.
Question
Kunal Dhamesha: Sure. Sure sir. And, secondly, for Dr. Satakarni Sir, would you say with all these changes, potential changes, in regulatory landscape, would you say that the plant compliance and good manufacturing practices would be the primary entry barrier for the new player for the biosimilar business given that PK studies, etc., those are not very costly to conduct? Dr. Satakarni Makkapati: Yeah, I mean I will repeat my answer.
Answer, satakarni makkapati
So, there are three things here. • One, you need to be able to develop an analytically high quality biosimilar. So, that's the first barrier. • Two, because if you develop a high quality biosimilar that is characterized well vis-à- vis originator biologic, the chances are , on a case-to-case basis you will get a Phase 3 waiver, which means that the companies which were investing anywhere between [USD] 50-150 million in conducting these clinical studies don't need to expend that much now. A PK/PD study with a strong immunogenicity data package, the immunogenicity requirements, I believe, will increase, Kunal. But having said that, the timelines will shrink, the investments will no longer be required to the extent that we were making before. So, all this is good.
Question
Kunal Dhamesha: Sure. And, Sir, lastly on where do we stand on the plant inspection from USFDA perspective? I mean, what is our preparedness here? When do we expect our first filing and USFDA to inspect the plant? Dr. Satakarni Makkapati: So, based on my earlier guidance, I was hoping to file a Trastuzumab with USFDA.
Answer, satakarni makkapati
But considering my supply commitments and it's a lyophilized 16 Aurobindo Pharma Limited 06 November 2025 product, recalculating my capacities and the utilization I realized that I will push down Trastuzumab to the latter half of next year. So, the first filing would now be Denosumab followed by Omalizumab. So, if we file it somewhere between April -June, then I expect the inspection to happen by the end of the Calendar Year 2026 with the USFDA. Kunal Dhamesha: Sure, Sir, it's helpful. And all the best. Thank you. Dr. Satakarni Makkapati: Thank you.
Question
Surya Patra: Thanks for the opportunity, Sir. My first question is on the European market. Is it possible to now share what is the injectable revenue mix within Europe now? And what is the margin performance for the entire European business now we are having?
Answer, v murlidharan
V. Murlidharan: Yeah, the injectable component is about 10%. We are touching [EUR] 100- million mark. Here, what I wish to state is not all of the products are in copious supplies, we are waiting for some of these products to kick in from Eugia III. So, at that time, we will be having a quantum jump that we expect in FY27. And, of course, the margin percentage wise, yes, we are touching at 20 levels, high teens.
Question
Surya Patra: Okay. Sir, is it right to think this way that given the large volume opportunity in the name of GLP what is upcoming , so to participate there aggressively in the majority of the emerging market are we becoming a bit aggressive and , hence, creating platforms and presence and positioning? And also, what is our thought process about India, about GLP also, if y can ? 17 Aurobindo Pharma Limited 06 November 2025 Yugandhar Puvvala: No, on the GLP piece, I think we have been very clear that we will be doing this product on our own at our Vizag plant and we will be in the second phase of launches and we are looking at filing the products across all markets sometime next year, okay.
Answer, s subramanian
S. Subramanian: On the India front, probably we may do some small acquisitions, may not be a big one. We will not do a big one because we'll just need to, I mean, slowly take off for the Indian market. As of now, we are doing around a turnover of something like ₹275-₹300 crore per year and probably we may take it by another ₹100 crore; like that only we will do. So, we will not go aggressive on the Indian market.
Question
Kunal Randeria: Sure. And, secondly, Sir, you did touch upon this M&A that you are looking to do. But you know, there was some news item earlier that you were looking to buy Zentiva 18 Aurobindo Pharma Limited 06 November 2025 and the payout could be like, you know, as much as US$5 billion. So, is this the kind of scale that you are comfortable doing?
Answer, s subramanian
S. Subramanian: No, see, Zentiva also, if you really see, assuming $4 billion, we have not given any number, assuming $4 billion the interest coverage will be more than 2 times, 2.5 times, right, even assuming 100% leverage. So, it all depends upon the case to case and Zentiva is a very unique case , that's what I've been telling.
Questions about this call
- When was the Aurobindo Pharma Q2 FY26 earnings call transcript filed?
- Aurobindo Pharma filed the transcript with the exchange on 11 Nov 2025. This page is built from that transcript.
- What does this page list?
- 57 statements from the transcript across 9 topics, 43 of them with a figure. Each statement is shown with the transcript sentence it came from.
- Are the analysts' questions included?
- Yes. 23 questions and management's answers are listed in the order they were asked, as the transcript prints them.
- Who wrote this page?
- DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.